These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1203181)

  • 1. Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments.
    Barry BW; Woodford R
    Br J Dermatol; 1975 Nov; 93(5):563-71. PubMed ID: 1203181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.
    Barry BW; Woodford R
    Br J Dermatol; 1976 Oct; 95(4):423-5. PubMed ID: 974028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoconstrictor activities and bio-availabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications.
    Barry BW; Woodford R
    Br J Dermatol; 1977 Nov; 97(5):555-60. PubMed ID: 588468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
    Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
    Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of admixture of commercially available corticosteroid ointments and/or creams on vasoconstrictor activity].
    Ohtani M; Yamada N; Takayama K; Kotaki H; Etoh T; Kariya S; Uchino K; Iga T
    Yakugaku Zasshi; 2002 Jan; 122(1):107-12. PubMed ID: 11828745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranking of glucocorticoid creams and ointments.
    Poulsen J; Rorsman H
    Acta Derm Venereol; 1980; 60(1):57-62. PubMed ID: 6153835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoconstrictor activities of some novel synthetic steroids in alcoholic solution.
    Barry BW; Brace AR
    J Invest Dermatol; 1975 Jun; 64(6):418-22. PubMed ID: 1141715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculin-induced inflammation.
    Schalla W; Schorning S
    Skin Pharmacol; 1991; 4(3):191-204. PubMed ID: 1768431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Various vagaries of vasoconstriction.
    Burdick KH
    Arch Dermatol; 1974 Aug; 110(2):238-42. PubMed ID: 4855376
    [No Abstract]   [Full Text] [Related]  

  • 11. Plethysmographic recordings of skin pulses. VI. Further measurements of the vasoconstriction produced by corticosteroids.
    Thune P
    Acta Derm Venereol; 1972; 52(4):303-7. PubMed ID: 4115885
    [No Abstract]   [Full Text] [Related]  

  • 12. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.
    Pershing LK; Silver BS; Krueger GG; Shah VP; Skelley JP
    Pharm Res; 1992 Jan; 9(1):45-51. PubMed ID: 1589409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations.
    Gibson JR; Kirsch J; Darley CR; Burke CA
    Br J Dermatol; 1983 Jul; 109 Suppl 25():114-6. PubMed ID: 6860578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dilution of proprietary corticosteroid ointments--an attempt to evaluate relative clinical potencies.
    Gibson JR; Darley C; Kirsch J; Saihan EM; Neild VS
    Br J Dermatol; 1982 Apr; 106(4):445-7. PubMed ID: 7073968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel intraindividual evaluation of the vasoconstrictory action and the anti-allergic activity of topical corticosteroids.
    Seidenari S; Di Nardo A; Mantovani L; Giannetti A
    Exp Dermatol; 1997 Apr; 6(2):75-80. PubMed ID: 9209888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objective determination of the bioavailability of dermocorticoids--influence of the formulation.
    Poelman MC; Leveque JL; Le Gall F
    Br J Dermatol; 1984 Jul; 111 Suppl 27():158-62. PubMed ID: 6743548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of a novel corticosteroid formulation, fluocinonide in "FAPG" base, in the blanching test.
    Coldman MF; Lockerbie L; Laws EA
    Br J Dermatol; 1971 Dec; 85(6):573-6. PubMed ID: 4947552
    [No Abstract]   [Full Text] [Related]  

  • 18. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations.
    Gibson JR; Kirsch JM; Darley CR; Harvey SG; Burke CA; Hanson ME
    Br J Dermatol; 1984 Jul; 111 Suppl 27():204-12. PubMed ID: 6378245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-induced vasoconstriction studied by xenon 133 clearance.
    Greeson TP; Levan NE; Freedman RI; Wong WH
    J Invest Dermatol; 1973 Oct; 61(4):242-4. PubMed ID: 4744028
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioavailability of proprietary corticosteroid containing ointments.
    Trikam DS; Morton DJ
    Cent Afr J Med; 1985 Mar; 31(3):57-8. PubMed ID: 4016908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.